公开(公告)号：US20240226035A1

公开(公告)日：2024-07-11

申请号：US18559087

申请日：2022-05-04

Applicant: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH

Inventor： O'Bryant Sid E.

IPC: A61K31/137 ,  A61K31/015 ,  A61K31/07 ,  A61K31/095 ,  A61K31/122 ,  A61K31/135 ,  A61K31/138 ,  A61K31/15 ,  A61K31/194 ,  A61K31/352 ,  A61K31/375 ,  A61K31/4045 ,  A61K31/42 ,  A61K31/421 ,  A61K31/4985 ,  A61K31/50 ,  A61K31/5375 ,  A61K33/00 ,  A61K33/04 ,  A61K38/06 ,  G16B25/10 ,  G16B40/20

CPC classification number: A61K31/137 ,  A61K31/015 ,  A61K31/07 ,  A61K31/095 ,  A61K31/122 ,  A61K31/135 ,  A61K31/138 ,  A61K31/15 ,  A61K31/194 ,  A61K31/352 ,  A61K31/375 ,  A61K31/4045 ,  A61K31/42 ,  A61K31/421 ,  A61K31/4985 ,  A61K31/50 ,  A61K31/5375 ,  A61K33/00 ,  A61K33/04 ,  A61K38/063 ,  G16B25/10 ,  G16B40/20

Abstract: The present invention includes a method for selecting a subject for a targeted treatment for Parkinson's Disease, the method comprising: obtaining or having obtained a sample from the subject; measuring in the blood or serum sample the expression level of one or more first biomarkers; comparing the level of expression of the one or more first biomarkers from the subject's sample with the expression level of a corresponding one or more first biomarkers from a statistical sample representative of biomarkers in a normal subject; and if the subject is found to have a statistically different expression level of the one or more biomarkers when compared to the expression level of the corresponding one or more biomarkers from the statistical sample, treating the subject with a monoamine oxidase inhibitor, an antioxidant, or both.

公开(公告)号：US20240241138A1

公开(公告)日：2024-07-18

申请号：US18559096

申请日：2022-05-06

Applicant: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH

Inventor： O'Bryant Sid E.

IPC: G01N33/68 ,  G01N21/76 ,  G16H50/20

CPC classification number: G01N33/6896 ,  G01N21/76 ,  G16H50/20 ,  G01N2333/4713 ,  G01N2333/4737 ,  G01N2333/524 ,  G01N2333/525 ,  G01N2333/5409 ,  G01N2333/5412 ,  G01N2333/5418 ,  G01N2333/5428 ,  G01N2333/70525 ,  G01N2333/7151 ,  G01N2333/745 ,  G01N2800/2835

Abstract: In one aspect, the present disclosure relates to a method for excluding a subject from the need for diagnostic testing for Parkinson's disease (PD). In another aspect, the present disclosure relates to a method for excluding a subject from recruitment into a clinical study for an investigational PD medication. In yet another aspect, the present disclosure relates to a method for screening a subject to determine whether the subject is ruled out as having PD, wherein the subjects who cannot be ruled out are administered a diagnostic test for PD, a treatment for PD, or a combination thereof.

公开(公告)号：US20240159776A1

公开(公告)日：2024-05-16

申请号：US18549183

申请日：2022-03-07

Applicant: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH

Inventor： O'Bryant Sid E.

IPC: G01N33/68 ,  A61K45/06 ,  G01N33/92

CPC classification number: G01N33/6896 ,  A61K45/06 ,  G01N33/6869 ,  G01N33/92 ,  G01N2333/525 ,  G01N2333/5409 ,  G01N2333/5412 ,  G01N2333/5418 ,  G01N2333/5428 ,  G01N2333/605 ,  G01N2333/62 ,  G01N2333/745 ,  G01N2800/2814 ,  G01N2800/56

Abstract: The present invention includes methods for detecting neurodegeneration and treating a subject that is of Mexican American or non-Hispanic white origin, the method comprising: obtaining a blood, plasma or serum sample; determining ethnicity of the subject; measuring one or more biochemical biomarkers; or measuring one or more protein biomarkers, or measuring both biochemical biomarkers and protein biomarkers; comparing the level of expression from the sample with a statistical sample representative of the subject of Mexican American or of non-Hispanic white origin, suspected of having neurodegeneration; and treating the subject with a treatment that targets neurodegeneration or neuronal injury, wherein the neurodegeneration or neuronal injury is measured by [18F]-fluorodeoxyglucose-PET, structural MRI, or CSF total tau.